T1DM Diagnostic Development Services

0
1KB

Type 1 diabetes mellitus (T1DM) culminates in the autoimmune destruction of the pancreatic β-cells, leading to insufficient production of insulin and development of hyperglycemia. Diagnosis of diabetes can help researchers efficiently analyze the causes of diabetes and advance the development of therapies. Ace Therapeutics can provide t1dm diagnostic markers development with more efficient function analysis.

Overview of T1DM Diagnosis

T1DM is a chronic autoimmune disease characterized by insulin deficiency as a consequence of autoimmune-mediated destruction of insulin producing pancreatic β-celIs. At the time of diagnosis, 80% to 90% of β-cells mass has been lost. Biomarkers including a combination of glucose, glycated molecules, C-peptide, and autoantibodies have been well established for the diagnosis of T1DM.

Fig 2. Pancreatic Changes and Immune Abnormalities in T1DM

Pancreatic Changes and Immune Abnormalities in T1DM (Alvin, C. P. The Journal of Clinical Investigation. 2021)

T1DM Diagnostic Markers

Although T1DM has been investigated for over a century, the etiology of the disease is still not fully understood. Until now, the biomarkers implemented in clinical practice such as glucose, HbAlc, C-peptide, and autoantibodies (AAb) were mainly diagnostic markers.

  • Glucose-related Biomarkers
    The blood-based glucose-related testing includes hemoglobin Ale (HbAlc) (a product of non-enzymatic glycation), the fasting plasma glucose (FPG), and oral glucose tolerance test (OGTT).
  • Autoantibody-based Biomarkers
    There are five commonly tested AAb markers used in the diagnosis of T1DM which include ICA (islet-cell cytoplasmic AAb), GADA (glutamic acid decarboxylase (GAD) AAb), IA-2A (insulinoma 2 (IA-2)- associated AAb), IAA (insulin AAb), ZNT8A (zinc transporter 8 AAb).
  • C-peptide
    Stimulated serum C-peptide level (as a surrogate for insulin) has been considered a consistent and sensitive measure of β-cell function and can be used to help differentiate autoimmune-diabetes from other diabetes subtypes.
  • Potential Novel Biomarkers
    Identifying novel biomarker candidates potentially useful for indicating the level of β-cell destruction, dysfunction, and mass as well as the ongoing immunological response in serum. There are some novel biomarkers including proteins, nucleic acids, and metabolites, et al., that can be detected by metabolomic techniques.

Fig 3. The Many Types of Potential Biomarkers

The Many Types of Potential Biomarkers (Yi, L.; et al. Translational Research. 2018)

Rechercher
Werbung
Catégories
Lire la suite
Networking
Triac Dimming Driver Market to Hit USD 178.4 Million by 2036
According to Future Market Insights (FMI), the global Triac Dimming Driver Market is...
Par Avi Ssss 2026-07-24 18:48:03 0 56
Shopping
Farbe ohne Lösungsmittel als Bestandteil nachhaltiger industrieller Beschichtungskonzepte
Nachhaltigkeit ist längst mehr als ein strategisches Ziel. In der Industrie entscheidet sie...
Par Colin Bell 2026-07-24 14:43:43 0 113
Food
Savory Flavor Modulators Market Set to Nearly Double by 2036 at 5.75% CAGR
NEWARK, Del., July 24, 2026 — The Savory Flavor Modulators Market is expected to witness...
Par Mane Ajit 2026-07-24 17:45:26 0 158
Art
Advanced Carbon Materials Market: Fueling the Next Industrial Revolution
Carbon Fiber Composites: Engineering the Future of Lightweight, High-Performance Materials Few...
Par Tony Stark 2026-07-24 14:49:30 0 92
Autre
Stick-Based Body Lotions Market in the U.S. Expands with L'Oréal as Global Revenue Reaches USD 24.9 Billion by 2036
The global Stick-Based Body Lotions Market is poised for steady growth as consumers...
Par Bablya Bhau 2026-07-24 18:33:33 0 77